Shares of Inflarx NV (NASDAQ:IFRX) have been assigned a consensus rating of “Hold” from the eleven analysts that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $6.20.
A number of analysts have recently weighed in on IFRX shares. Raymond James reiterated a “hold” rating on shares of Inflarx in a research note on Friday, July 19th. ValuEngine upgraded shares of Inflarx from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Guggenheim lowered shares of Inflarx from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $65.00 to $6.00 in a research note on Wednesday, June 5th. BMO Capital Markets lowered shares of Inflarx from an “outperform” rating to a “market perform” rating and set a $5.00 price objective on the stock. in a research note on Wednesday, June 5th. Finally, Zacks Investment Research lowered shares of Inflarx from a “hold” rating to a “sell” rating in a research note on Thursday, August 15th.
NASDAQ IFRX opened at $3.02 on Friday. The company has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $22.79. The stock has a market cap of $79.19 million, a P/E ratio of -2.16 and a beta of -1.49. Inflarx has a 12-month low of $2.45 and a 12-month high of $53.10.
Inflarx (NASDAQ:IFRX) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.11). On average, sell-side analysts forecast that Inflarx will post -2.25 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the company. Spark Investment Management LLC acquired a new stake in shares of Inflarx in the first quarter worth $359,000. Acadian Asset Management LLC acquired a new stake in shares of Inflarx in the second quarter worth $445,000. Atria Investments LLC acquired a new stake in shares of Inflarx in the second quarter worth $297,000. Victory Capital Management Inc. acquired a new stake in shares of Inflarx in the first quarter worth $3,094,000. Finally, Alpine Global Management LLC acquired a new stake in Inflarx during the second quarter valued at $95,000. Hedge funds and other institutional investors own 17.06% of the company’s stock.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.